Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm, February 7, 2024 - OncoZenge AB (publ) today announces that the company has filed a new patent application with the Swedish Patent and Registration Office (PRV). The patent strengthens the protection of the second generation of BupiZenge™ and the innovations made in connection with the recent reformulation. The new patent will provide strengthened IP protection for strategic partners and licensees upon approval.
In line with OncoZenge's strategy, the company has assessed the opportunities for complementary patents that further strengthen the protection for the second generation formulation of BupiZenge™ specifically, as well as for pain-relieving lozenges in general.
After thorough analysis of these opportunities, and in consultation with experts and patent attorneys, the company today announces that a new patent application has been filed. The patent application is based on insights and innovations made in the work with new formulations of the product, and was submitted to the Swedish Patent and Registration Office (PRV) on February 7, 2024.
Marie Mannerlöf, PhD, European patent attorney and CEO of Imariel AB comments "The collaboration with OncoZenge has been excellent and they have generated valuable data that strengthens our opportunities to obtain patents for BupiZenge™ globally. We have now filed a patent application with right to priority, and will proceed to ensure protection in strategically important markets internationally".
Stian Kildal, CEO of OncoZenge comments: "We have strong patent protection today but are pleased to confirm this opportunity to both strengthen, extend and geographically broaden the IP protection for our innovations in oral pain relief. For both OncoZenge and our potential licensees, extended patent protection is likely to represent significant commercial value over time."
With the new patent application, BupiZenge™ as pain reliever for oral mucositis, or future variants of BupiZenge™ for other indications, will be patent protected until 2045, subject to approval.
BupiZenge™ - Potential to be the leading treatment for oral pain.
For additional information, please contact:
Stian Kildal, CEO, mobile: +46 76 115 3797, e-mail: stian.kildal@oncozenge.se
Certified Adviser
OncoZenge's Certified Adviser is Carnegie Investment Bank AB (publ).
OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden
About OncoZenge
OncoZenge develops a novel, effective, safe and well-tolerated treatment for oral pain in conditions where currently available treatment options either do not achieve sufficient pain relief or are associated with significant side effects. BupiZenge™ is a new oral lozenge formulation of bupivacaine, an anaesthetic with decades of clinical experience. OncoZenge's lead indication is oral pain due to an inflammatory condition called oral mucositis that affects millions of patients receiving cancer treatment. Oral mucositis causes profound physical and psychological suffering, and is a large unmet medical need for an effective, opioid-sparing treatment option. BupiZenge™ has shown significantly better pain relief compared to standard of care in this indication in a Phase 2 trial. OncoZenge is headquartered in Stockholm, Sweden, and its share is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ.